Edesa Biotech reports positive exploratory data for paridiprubart in acute kidney injury
Edesa Biotech (NASDAQ:EDSA) announced favorable exploratory findings for its lead therapeutic candidate, paridiprubart, in patients suffering from acute kidney injury (AKI) and concurrent respiratory distress.










